Medicare Advantage plans get better than expected rate hike for 2018

Payments to insurers offering Medicare Advantage plans will increase by an average of 0.45 percent, according to the final rate notice issued by CMS, above the 0.25 percent bump in pay the agency had previously proposed.

When taking into account how plans code the diagnoses of its members, the average payment rate will increase by 2.75 percent.

“Medicare is committed to strengthening Medicare Advantage and the Prescription Drug Program by supporting flexibility and efficiency,” CMS Administrator Seema Verma, MPH, said in a statement. “These programs have been successful in allowing innovative approaches that give Medicare enrollees options that best fit their individual health needs.”

In a change from the proposed rates, the 2018 plan year won’t incorporate increased user of encounter data in plans’ risk adjustment calculation. CMS had initially proposed using 25 percent encounter data and 75 percent fee-for-service (FFS) data to determine risk scores, but after negative comments from groups like the American Hospital Association, the mix will be 85-15 in favor of the traditional FFS information.

The changes and better-than-expected payment increase were praised by stakeholder groups like the American Medical Group Association (AMGA).

“It is important that any risk adjustment in MA is fair and accurate,” Chet Speed, AMGA’s vice president of public policy, said in a statement to HealthExec. “With the flaws in the current Encounter Data System, CMS made the right choice in dropping the weight to 15%.”

In another win for the insurer, the 2018 rate announcement and call letter delayed the transition to terminate bidding on “employer group waiver plans” for employers and union which offer retirees Medicare Advantage coverage. Payment would instead be a lump sum based on county-level bids.

Rather than complete the two-year phase-in of this switch, CMS said 2018 will continue the formula utilized in 2017, a bid-to-benchmark ratio with employer plan payments based half on their bids and half on the county-level benchmarks.  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.